FindTrial
Sign In

MESNA EG 100 mg/ml

DRUG2 trials

Sponsors

Institut Gustave Roussy, Assistance Publique Hopitaux De Paris

Conditions

Non-seminomatous germ-cell tumors (including testisparaneoplastic sensory neuropathy with anti-Hu antibodiesretroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified as poor prognosis according to IGCCCG criteria.

Phase 2

A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06))
RecruitingCTIS2023-505040-19-00
Institut Gustave RoussyNon-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified as poor prognosis according to IGCCCG criteria.
Start: 2023-04-11Target: 150Updated: 2025-03-14
Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplastic sensory neuropathy (NESPA).
RecruitingCTIS2023-506942-22-01
Assistance Publique Hopitaux De Parisparaneoplastic sensory neuropathy with anti-Hu antibodies
Start: 2025-01-10Target: 21Updated: 2025-04-23